NEW ORLEANS – A Texas man has filed suit against several pharmaceutical companies,
alleging that they fraudulently represented Xarelto to the medical and health care community.
Michael Godfrey filed a complaint on April 5 in the U.S. District Court for the Eastern District of Louisiana against
Jansen Research & Development LLC, Jansen Ortho LLL, Jansen Pharmaceuticals Inc., Johnson & Johnson Co., Bayer Pharma AG, Bayer Corp., Bayer Healthcare Pharmaceuticals Inc., Bayer Healthcare AG, Bayer AG et al. citing alleged fraud, breach of express warranty, negligent misrepresentation and other counts.
According to the complaint, the plaintiff alleges that he has suffered economic and non-economic damages, serious and dangerous side effects, life-threatening bleeding, as well as other severe and personal injuries which are permanent in nature. The plaintiff holds the defendants responsible because the defendants allegedly designed, researched, manufactured, tested, advertised, promoted, marketed distributed and sold Xarelto. They allegedly also failed to properly investigate, research, study and define, fully and adequately, the safety profile of Xarelto; failed to adequately test Xarelto; failed to provide adequate warnings; failed to disclose the need for dose adjustments; failed to provide adequate instructions; and failed to warn the medical professionals that there is no effective agent to reverse the effects of Xarelto.
The plaintiff requests a trial by jury and seeks compensation for damages in excess of the jurisdictional amount, prejudgment and post-judgment interest, reasonable attorneys’ fees and costs and for such other and further relief as the court may deem just and proper. He is represented by Charles M. Thomas of Huber, Slack, Thomas & Marcelle LLP in New Orleans.
U.S. District Court for the Eastern District of Louisiana Case number 2:16-cv-02814